University of Michigan

Jeanne Stuckey

Shaomeng Wang

Liu Liu

Longchuan Bai

Jennifer Lynn Meagher

Duxin Sun

Donna McEachern

Chao-Yie Yang

Arul M Chinnaiyan

Angelo Aguilar

Bing Zhou

Yujun Zhao

Irfan A Asangani

Ruijuan Luo

Xu Ran

Xiaoqin Li

Haibin Zhou

Zaneta Nikolovska-Coleska

Jianfeng Lu

Yang Hu

Hacer Karatas

Bo Wen

Lei Miao

Ting Zhao

Ahmed Mady

Ester Fernandez-Salas

Hollis Showalter

David M Markovitz

Hashim M Al-Hashimi

Rohan Rej

Liyue Huang

Jianfang Chen

Yi Sun

Liangyou Rui

Tianfeng Xu

Shilin Xu

Fardokht Abulwerdi

Changwei Wang

Renqi Xu

Loic Salmon

Mi Wang

Donna McEachem

Daniel M Boudreaux

Donna Mceacherm

The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, A, E, E, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.

Small molecule STAT protein degraders

The present disclosure provides compounds represented by Formula I: wherein R, R, R, and Rare as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

Imidazopyrimidines as EED inhibitors and the use thereof

The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R, R, R, R, R, R, R, R, R, X, Z, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer. 

Piperidines as covalent menin inhibitors

Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

Covalent small molecule DCN1 inhibitors and therapeutic methods using the same

Provided herein are chemical compounds, methods for their discovery, and their therapeutic and research use. Further provided herein are antiviral and antimicrobial lectin compounds and methods of their use.

Lectins and uses thereof

Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.

BET bromodomain inhibitors and therapeutic methods using the same

The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R, A, B, B, G, X, Y, Y, and Yare as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having benzoic acid structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

Small molecule inhibitors of Mcl-1 and uses thereof

9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having pyrazolopyridine structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.

Small molecule inhibitors of MCL-1 and uses thereof

Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.

Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

Growing community of inventors

Fenton, MI, United States of America

Jeanne Stuckey